European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
The European Commission approved Gilead's Trodelvy as a first-line monotherapy for metastatic triple-negative breast cancer patients who are not candidates for PD-(L)1 inhibitor therapy. This makes Trodelvy the first antibody-drug conjugate approved for this specific patient population in the European Union. The authorization was supported by data from the Phase 3 ASCENT-03 study, where Trodelvy demonstrated a 38% reduction in the risk of disease progression or death compared to standard chemotherapy.
Key figures
- Phase of trial
- Phase 3
- Risk reduction
- 38%
- Patients treated since 2020
- 75000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.